Recombinant  expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice by unknown
RESEARCH Open Access
Recombinant Lactococcus lactis expressing
porcine insulin-like growth factor I
ameliorates DSS-induced colitis in mice
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Abstract
Background: Insulin-like growth factor I (IGF-I) is one important family of growth factors, which plays key role in
intestinal growth, regeneration, and damage repair. However, the low natural abundance of IGF-I limits its research
opportunities and practical application in the fields of medicine and animal husbandry. In this study, a tandem
repeat strategy was used to express three copies of the same pIGF-I3 protein in L. lactis. The activity of recombinant
pIGF-I3 (rpIGF-I3) was further examined by a mouse model of dextran sulfate sodium (DSS)–induced colitis. In
addition, the potential of recombinant L. lactis expressing pIGF-I3 to reduce inflammatory disease was evaluated.
Results: pIGF-I3 could be expressed in L. lactis by the detection of SDS–PAGE and Western blot. Experimental colitis
was induced in BALB/c mice by administration of 5 % DSS in drinking water, and the clinical symptoms were
observed in DSS-treated mice. Oral administration of recombinant L. lactis expressing pIGF-I3 improved the colonic
architecture, and significantly reduced the increase of colonic damage score (P < 0.05). Furthermore, recombinant
L. lactis expressing pIGF-I3 treatment significantly reduced serum DAO activity and colonic MPO level, and elevated
colonic occludin level compared to the DSS group (P < 0.05).
Conclusions: The pIGF-I3 expressed in L. lactis has good biological activity, and oral administration of recombinant L.
lactis expressing pIGF-I3 attenuated the symptoms and development of DSS-induced colitis in mice. These suggested
that L. lactis could be a potential host bacterium for production and delivery of IGF-I against intestinal diseases.
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Background
Insulin-like growth factor I (IGF-I) is a 7.5 kDa single-
chain polypeptide with 70 amino acid residues, which is
considered as one important family of growth factors [1].
IGF-I is synthesized in the liver, produced locally in many
tissues including the gastrointestinal tract, and regu-
lated by growth hormone and nutrition [2, 3]. It
exerts biological effect primarily through specific type
I IGF receptor, which is distributed throughout the
intestines of some mammalian, such as human, rat
and pig [4, 5]. IGF-I can stimulate the proliferation
and differentiation of many cell types, enhance DNA
synthesis and protein content, inhibit cell apoptosis,
and play an important role in the development and
growth of animals [6–11]. In addition, IGF-I particu-
larly displays trophic effect on the gastrointestinal
tract, which has received considerable attention in the
fields of medicine and animal husbandry.
Studies have indicated that IGF-I not only stimu-
lated intestinal growth but also potentially regulated
intestinal regeneration and repair. High concentra-
tions of IGF-I in maternal colostrum and milk modu-
lated neonatal gastrointestinal tract development and
function [12]. IGF-I supplementation in newborn pro-
moted nutrient and electrolyte absorption, improved
intestinal morphology, and increased disaccharidase
activity [13, 14]. In addition, orally or systemically
administered IGF-I accelerated intestinal repair in ani-
mal models of intestinal diseases, such as experimental
colitis, intestinal mucositis, and experimental radi-
ation enteritis [15–17]. IGF-I has showed the potential
to exert anti-inflammatory action by inhibiting pro-
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inflammatory cytokine production and increasing anti-
inflammatory cytokine production in acute pancrea-
titis [18].
IGF-I has important biological functions, but low
abundance in natural sources is a crucial factor to limit
its further study and practical application. Genetic
engineering technique is a good method for low-cost
production of functional proteins by large-scale culture
of recombinant bacteria. Therefore, a safe and highly
effective expression system is needed to produce func-
tional proteins for the health of humans and animals.
Human IGF-I has been produced in E. coli, but recombin-
ant protein was expressed in insoluble inclusion bodies,
and needed to be refolded into an active conformation by
denaturation and renaturation treatment [19]. Probiotics
has been reported to improve host health and modulate
the gastrointestinal functions in human and animals [20].
Lactococcus lactis (L. lactis) is a food-grade microorgan-
ism widely used in the food fermentation industry and
generally regarded as a safe probiotic [21]. Nonpathogenic
and noninvasive L. lactis is an ideal candidate to produce
and deliver therapeutic proteins to mucosal system of
intestine with simple operation [22]. Furthermore, the
bacterium can survive passage through human intestines
and does not colonize the intestinal tract [23]. Foreign
proteins expressed in L. lactis do not require to be puri-
fied, may be taken together with recombinant L. lactis,
and can perform specific biological activity in body [24].
In the present study, three same genes of mature
porcine IGF-I (pIGF-I3) were designed by tandem repeat
strategy, and a nisin-controlled gene expression system
(NICE) was used to express pIGF-I3 in L. lactis. The
activity of recombinant pIGF-I3 (rpIGF-I3) was examined
by using a mouse model of dextran sulfate sodium
(DSS)–induced colitis, and the potential of recombinant
L. lactis expressing pIGF-I3 to reduce inflammatory
disease was evaluated.
Results and discussion
Expression of pIGF-I3 in L. lactis
The gene pIGF-I3 was optimized based on codon bias of
L. lactis, and the restriction sites and a stop codon were
added to the 3′ or 5′ end of the optimized pIGF-I3 gene.
The resulting fragment was cloned into pNZ8148 to
generate pNZ8148-pIGF-I3, which had been successfully
transformed into L. lactis NZ9000 by sequence identifi-
cation. Whole cell lysates of L. lactis NZ9000 (pNZ8148-
pIGF-I3) were analyzed by using sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
to determine whether pIGF-I3 could be expressed in L.
lactis (Fig. 1a). The protein electrophoresis of the gel
revealed an additional band of approximately 23 kDa,
which just corresponded to the target protein of pIGF-
I3. However, L. lactis NZ9000 (pNZ8148) as control
strain did not have this band. The rpIGF-I3 was further
assayed by Western blot, and the result revealed that the
corresponding immunoreactive band was present on the
membrane from L. lactis NZ9000 (pNZ8148-pIGF-I3)
(Fig. 1b). These results indicated that L. lactis was able
to express pIGF-I3.
Colon length analysis
The reduction of colon length was an indirect
marker of colonic inflammation and often observed
in ulcerative colitis patients or animal models [25].
Treatment with 5 % DSS significantly shortened
colon length (31.67 %) compared with the control
group (P < 0.05). However, oral administration of re-
combinant L. lactis expressing pIGF-I3 or L. lactis
improved the shortening of colon length (Fig. 2).
Dietary colostrum-borne IGF-I during one week has
been reported to promote the growth of neonatal in-
testinal tissue and up-regulated type I IGF receptors
in newborn calves [26]. In addition, IGF-I treatment
partially reversed significant reduction of colon
length in DSS-treated rats, and reduced the thick-
ness of submucosal and muscularis externa layers
[27]. In the present study, oral administration of re-
combinant L. lactis expressing pIGF-I3 significantly
increased colon length by approximately 18.03 %
compared with the DSS group (P < 0.05), but no sig-
nificant difference was found between the recombin-
ant L. lactis and L. lactis groups. These suggested
that recombinant L. lactis expressing pIGF-I3 attenu-
ated the shortening of colon length due to the use
of L. lactis as a host bacterium, and took a certain
protective effect on intestinal injury.
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Fig. 1 Detection of rpIGF-I3 by SDS–PAGE (a) and Western blot
(b) analysis of cell lysates of L. lactis NZ9000 (pNZ8148-pIGF-I3)
induced with nisin. a Lanes 1 and 2, cell lysates of L. lactis NZ9000
(pNZ8148-pIGF-I3); lanes 3 and 4, cell lysates of L. lactis NZ9000
(pNZ8148); lane 5, molecular weight marker. b Lanes 1 and 3, cell
lysates of L. lactis NZ9000 (pNZ8148); lanes 2 and 4, cell lysates of
L. lactis NZ9000 (pNZ8148-pIGF-I3)
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Colonic damage score and histological analysis
Colonic damage was observed on the 11th day of the
experiment by histological detection (Fig. 3). DSS treat-
ment revealed a typical ulcer that involved most of intes-
tine mucosa, seriously affected colonic architecture, and
led to a significant increase in colonic damage score
(CDS) compared with the control group (P < 0.05). As
vector control, L. lactis strain treatment showed visible
large ulcer surface, peripheral epithelial cells crawling to
the ulcer surface, damage being repaired in the colonic
tissue and a significant reduction CDS compared with
the DSS group (P < 0.05). In the recombinant L.
lactis group, the morphological structure of colonic
tissue became relatively complete, and colon displayed
visible small ulcer surface. In addition, oral adminis-
tration of recombinant L. lactis expressing pIGF-I3
further improved colonic damage, and significantly
reduced CDS compared with the DSS and L. lactis
groups (P < 0.05). These results suggested a direct
action of recombinant L. lactis expressing pIGF-I3 on
the colonic epithelium.
It has been reported that exogenously applied IGF-I
increased the numbers of goblet cells of the colonic
epithelium, and significantly increased histological healing
scores in an experimental model of colitis [27, 28].
Administration of IGF-I to cirrhotic rats improved intes-
tinal histopathological changes and significantly reduced
endotoxaemia [29]. Furthermore, IGF-I treatment restored
gut weight to control levels and increased the
number of crypt mitoses in rats with colon anasto-
moses [30]. In the present study, oral administration
of recombinant L. lactis expressing pIGF-I3 reduced
intestinal damage, and maintained the relative integrity of
intestinal tract in DSS-treated mice.
Although oral administration of recombinant L. lactis
expressing pIGF-I3 significantly increased colon length
and reduced CDS compared with the DSS group, the
colon length and CDS was only partially improved. This
Fig. 2 Effect of oral administration of L. lactis NZ9000 (pNZ8148-
pIGF-I3) on colon length in mice (n = 8) treated with DSS-induced
colitis. The statistical differences between groups were evaluated by
one-way ANOVA with Duncan’s multiple comparison. Group 1
(control ) received normal drinking water. Group 2 (DSS )
received DSS solution in drinking water. Group 3 (L. lactis )
received the same treatment of DSS as Group 2. Meanwhile, these
mice orally administered with L. lactis NZ9000 (pNZ8148). Group 4
(recombinant L. lactis ) received the same treatment of DSS as
Group 2. Meanwhile, these mice orally administered with L. lactis
NZ9000 (pNZ8148- pIGF-I3). Same letters between the groups
indicate no statistically significant difference (P > 0.05), and
different letters indicate statistically significant difference (P < 0.05)
DSS L. lactis
Control Revcombinant L. lactis
Fig. 3 Effect of oral administration of L. lactis NZ9000 (pNZ8148-pIGF-I3)
on histopathological changes and colonic damage score in mice (n = 6)
treated with DSS-induced colitis. The statistical differences between
groups were evaluated by one-way ANOVA with Duncan’s multiple
comparison. Group 1 (control ) received normal drinking water. Group
2 (DSS ) received DSS solution in drinking water. Group 3 (L. lactis )
received the same treatment of DSS as Group 2. Meanwhile,
these mice orally administered with L. lactis NZ9000 (pNZ8148).
Group 4 (recombinant L. lactis ) received the same treatment
of DSS as Group 2. Meanwhile, these mice orally administered
with L. lactis NZ9000 (pNZ8148-pIGF-I3). Same letters between
the groups indicate no statistically significant difference (P > 0.05), and
different letters indicate statistically significant difference (P < 0.05)
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may perhaps be associated with the choice of animal
models. In the present study, an acute DSS model of
colitis is induced by continuous administration of 5 %
DSS for 7 consecutive days. However, susceptibility of
mice to DSS was affected by the concentration and mo-
lecular weight of DSS, genetic and microbiological
factors of animals [31]. These were likely to influence
the results of recombinant L. lactis expressing pIGF-
I3 treatment. Genetic variations were well known to
be important in intestinal dysfunction, such as IBD.
IL-10-deficient (IL-10−/−) mice, a gene-targeted mutation,
spontaneously develop a chronic enterocolitis due to a
dysregulated immune response to ordinary enteric anti-
gens [32]. This model might be more suitable to evaluate
biological activity of the rpIGF-I3.
Colonic myeloperoxidase activity analysis
Myeloperoxidase (MPO) is an enzyme produced in
leukocytes, and its activity is linearly related to neutro-
phil infiltration of the colon as an index of inflammatory
response under pathological conditions [33, 34]. In the
present study, DSS treatment significantly increased
MPO activity by approximately 65.51 % compared with
the control group (P < 0.05), and the L. lactis group
revealed a reduction trend on MPO activity (Fig. 4). Oral
administration of recombinant L. lactis expressing pIGF-I3
significantly reduced MPO activity by approximately 20.83
% compared with the DSS group (P < 0.05), and showed
no significant difference compared with the control group.
A similar result was shown that IGF-I inhibited the
increases of gastric MPO activity and immunofluores-
cence intensity of MPO in the gastric mucosa, and
reduced stress-induced mucosal injury in mice [35]. The
results of this study suggested that recombinant L. lactis
expressing pIGF-I3 has an anti-inflammatory effect,
might reduce intestinal mucosa injury partly because
of inhibiting the accumulation of neutrophils in the
colonic mucosa. In addition, L. lactis as a host bacter-
ium contributed to beneficial effect on recombinant
L. lactis expressing pIGF-I3 in the prevention of intes-
tinal inflammation.
Diamine oxidase activity and occludin level analysis
Diamine oxidase (DAO) is a cytoplasmic enzyme exist-
ing in the villus cytoplasm of intestinal stratum supra-
vasculare. It is released and enters into the bloodstream
when the intestinal mucosa is damaged. Therefore, serum
DAO activity is often used as a marker of intestinal muco-
sal integrity [36]. In this study, DSS treatment significantly
increased serum DAO activity by approximately 71.21 %
compared with the control group (P < 0.05), and oral
Fig. 4 Effect of L. lactis NZ9000 (pNZ8148-pIGF-I3) on colonic
MPO activity in mice (n = 6) treated with DSS-induced colitis.
The statistical differences between groups were evaluated by one-way
ANOVA with Duncan’s multiple comparison. Group 1 (control )
received normal drinking water. Group 2 (DSS ) received DSS
solution in drinking water. Group 3 (L. lactis ) received the same
treatment of DSS as Group 2. Meanwhile, these mice orally
administered with L. lactis NZ9000 (pNZ8148). Group 4 (recombinant L.
lactis ) received the same treatment of DSS as Group 2. Meanwhile,
these mice orally administered with L. lactis NZ9000 (pNZ8148-pIGF-I3).
Same letters between the groups indicate no statistically significant
difference (P > 0.05), and different letters indicate statistically significant
difference (P < 0.05)
Fig. 5 Effect of L. lactis NZ9000 (pNZ8148-pIGF-I3) on serum DAO
activity in mice (n = 6) treated with DSS-induced colitis. The
statistical differences between groups were evaluated by one-way
ANOVA with Duncan’s multiple comparison. Group 1 (control )
received normal drinking water. Group 2 (DSS ) received DSS
solution in drinking water. Group 3 (L. lactis ) received the same
treatment of DSS as Group 2. Meanwhile, these mice orally administered
with L. lactis NZ9000 (pNZ8148). Group 4 (recombinant L. lactis
) received the same treatment of DSS as Group 2. Meanwhile,
these mice orally administered with L. lactis NZ9000 (pNZ8148-pIGF-I3).
Same letters between the groups indicate no statistically significant
difference (P > 0.05), and different letters indicate statistically
significant difference (P < 0.05)
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administration of L. lactis did not inhibit the increase of
DAO activity (Fig. 5). However, oral administration of
recombinant L. lactis expressing pIGF-I3 significantly
reduced DAO activity by approximately 49.68 % com-
pared with the DSS group (P < 0.05). No significant differ-
ence was found between the recombinant L. lactis and
control groups.
Tight junction (TJ) is the most important structure of
intestinal barrier. It maintains cell polarity and regulates
the permeability of ions, macromolecules, and cells
through the paracellular pathway [37]. Occludin is an
integral membrane protein localizing at TJ, and per-
forms important functions in TJ assembly and mainten-
ance [38]. Colonic occludin concentration was also
measured in colon tissue. DSS treatment significantly
decreased occludin level by approximately 33.53 %
compared with the control group (P < 0.05) (Fig. 6). As
vector control, L. lactis strain treatment enhanced occlu-
din level compared with the DSS group, but no significant
difference was found between the two groups. Oral
administration of recombinant L. lactis expressing pIGF-I3
significantly increased occludin level by approximately
31.25 % compared with the DSS group (P < 0.05). No sig-
nificant difference was found between the recombinant L.
lactis and control groups.
IGF-I has been shown to maintain a paracellular bar-
rier function in cells by the expression and distribution
of TJ proteins and inhibit the increase of plasma DAO
activity [39, 40]. In the present study, oral administration
of recombinant L. lactis expressing pIGF-I3 prevented
the increase of serum DAO activity, enhanced colonic
occludin level in mice with colitis, and regulated their
levels near to normal concentration. The results showed
the consistency with histological examinations. These
suggested that oral administration of recombinant L.
lactis expressing pIGF-I3 protected the intestinal barrier
and integrity, and decreased colitis-induced elevated
epithelial permeability.
Conclusions
In this study, we constructed recombinant L. lactis
expressing pIGF-I3 and investigated its effect on intes-
tinal regeneration and repair by using a mouse model of
DSS-induced colitis. The results indicated that rpIGF-I3
has good biological activity. Oral administration of
recombinant L. lactis expressing pIGF-I3 attenuated
DSS-induced colitis and protected intestinal function by
improving CDS, MPO and DAO activities, and inhibit-
ing the increase of colonic occludin level. These
suggested that IGF-I expressed in L. lactis could be a
good way to treat intestinal diseases.
Methods
Bacterial strains, plasmids, and growth conditions
L. lactis NZ9000 and plasmid pNZ8148 of the NICE
system were purchased from NIZO Food Research. L.
lactis was grown as a host bacterium in an M17 medium
(Difco, Sparks, Maryland, USA) supplemented with 0.5
% (w/v) glucose at 30 °C without agitation. Escherichia
coli MC1061 was used as an intermediate cloning host
and grown in Luria–Bertani medium with agitation at 37
°C. Chloramphenicol was used at a concentration of 10
μg/mL to select recombinant strains.
Optimization of codon and construction of recombinant
L. lactis
pIGF-I is a small protein composed of 70 amino acid
residues with a molecular weight of 7.5 kDa. In order to
prevent pIGF-I degradation by cellular enzyme, three
copies of mature pIGF-I (pIGF-I3) with the same nucleo-
tide sequence were designed by tandem repeat strategy
according to pIGF-I mRNA (GenBank accession no.
M31175.1), and separated by a 18 bp linker that yields
the amino acid sequence GGGGSG between the copies
of pIGF-I. The gene sequence of the designed pIGF-I3
was further optimized based on codon bias of L. lactis
(http://www.kazusa.or.jp/codon), and low-usage codons
were replaced by high-usage ones. NcoI restriction site
(CCATGG) containing a start codon (ATG) was added
Fig. 6 Effect of L. lactis NZ9000 (pNZ8148-pIGF-I3) on colonic
occludin level in mice (n = 6) treated with DSS-induced colitis. The
statistical differences between groups were evaluated by one-way
ANOVA with Duncan’s multiple comparison. Group 1 (control )
received normal drinking water. Group 2 (DSS ) received DSS
solution in drinking water. Group 3 (L. lactis ) received the same
treatment of DSS as Group 2. Meanwhile, these mice orally administered
with L. lactis NZ9000 (pNZ8148). Group 4 (recombinant L. lactis )
received the same treatment of DSS as Group 2. Meanwhile, these
mice orally administered with L. lactis NZ9000 (pNZ8148-pIGF-I3).
Same letters between the groups indicate no statistically significant
difference (P > 0.05), and different letters indicate statistically
significant difference (P < 0.05)
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to the 5′ end of the first copy, a stop codon (TAA) and
HindIII restriction site (AAGCTT) were added to the 3′
end of the third copy. Furthermore, the G + C content
was adjusted to 40 to 70 %, and the resulting frag-
ment (665 bp) was synthesized by Shanghai Shengong
Biotechonology (Shanghai, China).
The resulting fragment was cloned into NcoI and
HindIII sites of pNZ8148 vector, and this recombinant
vector was transformed into E. coli MC1061. The
colonies were selected by resistance to chloramphenicol,
confirmed by digestion with NcoI and HindIII, and
further sequenced by Invitrogen (Shanghai, China). The
positive plasmid named pNZ8148-pIGF-I3 was then
transformed into L. lactis NZ9000 by electroporation.
Expression and identification of rpIGF-I3 in L. lactis
The recombinant protein of pIGF-I3 was identified by
SDS–PAGE and Western blot as previously described
[41]. Briefly, L. lactis NZ9000 (pNZ8148-pIGF-I3) and L.
lactis NZ9000 (pNZ8148) were inoculated (3 % v/v) in
fresh medium and grown to an optical density at OD600
= 0.4. Then these strains were induced with 10 ng/mL of
nisin (Sigma-Aldrich, USA) and continued to grow for 3
h. After harvested by centrifugation, the strains were
suspended in 10 mM Tris–HCl buffer (pH 8.0) contain-
ing 1 mg/mL lysozyme and incubated on ice for 30 min.
The strain extracts were obtained by centrifugation for
10 min, and 10 μL of aliquots was analyzed by using 10 %
SDS–PAGE. Subsequently, the gel with proteins was trans-
ferred to polyvinylidene fluoride membrane (Millipore,
Bedford, MA, USA) using a semidry blotting apparatus
(Bio-Rad, Hercules, CA, USA). The membrane was incu-
bated with primary anti-IGF-I monoclonal antibody
(Abcam, Cambridge, MA, USA) and HRP-conjugated goat
polyclonal secondary antibody (Abcam), followed by 3,3′-
diaminobenzidine as the substrate for visualizing bands.
Stains preparation for animal experiment
L. lactis NZ9000 (pNZ8148-pIGF-I3) and L. lactis
NZ9000 (pNZ8148) were grown and induced as de-
scribed above. Stains were collected and washed three
times with 0.01 mol/L sterile phosphate-buffered saline
(PBS) after centrifugation. Finally, L. lactis NZ9000
(pNZ8148-pIGF-I3) and L. lactis NZ9000 (pNZ8148)
were suspended in PBS to a concentration of 4 × 1012
CFU, respectively.
Animals and DSS-induced colitis
Eight-week-old female BALB/c mice were purchased
from SLAC Laboratory Animal Central (Shanghai,
China). These pathogen-free mice were housed in filter-
top cages at experimental animal room under standard
condition, and were provided with ad libitum water and
food. All animal protocols were carried out in strict
accordance with the guidelines of the Animal Care and
Use Committee of Zhejiang, China, and approved by the
Committee on the Ethics of Animal Experiments of
Zhejiang Academy of Agricultural Sciences, China.
Animals were randomly allotted in five groups, eight
mice per group. Mice were treated at 6 weeks of age.
Group 1 (control group) received normal drinking water
for 10 days. Group 2 (DSS group) received 5 % w/v DSS
solution (MW 36,000–50,000; MP Biomedicals, LLC,
Illkirch, France) in drinking water for 7 consecutive days
and followed with normal drinking water for 3 days.
Group 3 (L. lactis group) received the same treatment of
DSS as Group 2. Meanwhile, these mice were orally
administered with 4 × 1012 CFU of L. lactis NZ9000
(pNZ8148) for 10 days. Group 4 (recombinant L. lactis
group) received the same treatment of DSS as Group
2. Meanwhile, these mice were orally administered
with 4 × 1012 CFU of L. lactis NZ9000 (pNZ8148-pIGF-I3)
for 10 days.
All mice were anesthetized with pentobarbital so-
dium and killed on the 11th day of the experiment.
The colons of all mice were removed, and the length
was measured. In addition, colon and blood samples
of six mice in each group were randomly selected for
the following analysis. Samples of the distal colon
approximately 1 cm were immersion-fixed for 24 h in
10 % v/v formalin buffer for histological assay. Other
colonic segments were frozen at −80 °C to analyze
MPO activity, and occludin level. Before they were
killed, blood samples of mice were collected by
orbital puncture on the 11th day of the experiment.
Serum was obtained for analysis of DAO activity by
centrifugation at 1500 × g for 15 min at 4 °C.
Histology analysis for colonic damage score
Tissue samples of colon were embedded in paraffin
following standard histology procedures. Subsequently,
the blocks were cut into sections of 4 μm thickness,
which were stained routinely with hematoxylin and
eosin, and microscopically examined. Colonic damage
was graded in a blinded manner as described by
Dieleman et al. [42]. The colonic sections were briefly
assessed based on the amount of inflammation (acute
and chronic; scored from 0 to 3), the depth of inflam-
mation, and the amount of crypt damage or rege-
neration (scored from 0 to 4). The results were
quantified for the percentage involvement in the
disease process as follows: (1) 1 to 25 %, (2) 26 to 50 %, (3)
51 to 75 %, and (4) 76 to 100 %. The score of each
colonic section was provided for each feature by
establishing the product of the grade for that feature
and the percentage involvement. Finally, the colonic
damage score (CDS) of each mice was the sum of
these scores.
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Determination of colonic myeloperoxidase activity and
occludin level
MPO activity was measured in colon tissue using the
Assay Kit following the manufacturer’s instruction
(Nanjing Jiancheng Bio-engineering Co., Ltd., China).
One unit of MPO activity was defined as H2O2 broken
into 1 mol in each gram of tissue at 37 °C, and the result
was finally expressed as units per gram of total colon
protein. The occludin level of colon tissue was analyzed
using the Mouse ELISA kit (Nanjing Jiancheng Bio-
engineering Co., Ltd.) and expressed as nanograms per
milligram of total colon protein.
Measurement of serum diamine oxidase activity
The activity of serum DAO was further measured using
the Assay Kit following the manufacturer’s instruction
(Nanjing Jiancheng Bio-engineering Co., Ltd.). DAO ac-
tivity was expressed as units per liter of serum volume.
Statistical analysis
All data were presented as means ± standard deviation for
each group. The statistical differences between groups
were evaluated by one-way ANOVA with Duncan’s
multiple comparison. P < 0.05 was considered statistically
significant.
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